Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to boost immune attack on hard-to-treat GI cancers

NCT ID NCT03539822

Recruiting now Disease control Sponsor: Anwaar Saeed Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that cannot be removed by surgery will take part. The goal is to find the best dose and see if tumors shrink.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus colorectal adenocarcinoma colorectal cancer colorectal neoplasm esophageal adenocarcinoma gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER ESOPHAGEAL ADENOCARCINOMA GASTRIC CANCER HEPATOCELLULAR CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Kansas Cancer Center

    TERMINATED

    Westwood, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.